Table 3.
Multiple linear regression on the changes of anemia-related variables after HDF conversion in hemodialysis patients
| Laboratory measure | Patient groups | Changes after conversion | Univariate analysis | Multivariate analysisa | ||
|---|---|---|---|---|---|---|
| Unstandardized β (95% CI) | P value | Unstandardized β (95% CI) | P value | |||
| Hemoglobin (g/dL) | HD group | 0.2 ± 1.3 | Reference | Reference | ||
| OL-HDF group | 0.6 ± 1.2 | 0.47 (0.04, 0.90) | 0.034 | 0.74 (0.18, 1.30) | 0.010 | |
| Ferritin (ng/mL) | HD group | 93.2 ± 239.9 | Reference | Reference | ||
| OL-HDF group | 201.3 ± 493.1 | 108.1 (-1.9, 218.1) | 0.054 | 106.6 (-7.1, 220.2) | 0.066 | |
| TSAT (%) | HD group | -2.2 ± 15.4 | Reference | Reference | ||
| OL-HDF group | -4.2 ± 18.7 | -2.1 (-7.6, 3.5) | 0.467 | 3.4 (-3.2, 10.0) | 0.309 | |
| ESA dose (IU/kg/wk)b | HD group | -115.7 ± 189.7 | Reference | Reference | ||
| OL-HDF group | -170.5 ± 257.1 | -54.8 (-126.1, 16.5) | 0.131 | -46.6 (-119.1, 25.9) | 0.206 | |
Data regarding changes in values are expressed as mean ± standard deviation.
CI, confidence interval; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; HDF, hemodiafiltration; OL-HDF, online-HDF; TSAT, transferrin saturation.
aAdjusted for age, sex, etiology of end-stage renal disease, time on dialysis, single-pool Kt/V, high sensitivity C-reactive protein (hs-CRP), use of ESA, and use of intravenous iron. bFor darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, the dose per week was multiplied by 200 to convert the units from micrograms to international units (Ref. [14]).